文献速递消化道肿瘤放疗放疗物理与技术

直肠癌MR引导放疗剂量递增的安全性及早期器官保留结果(preRADAR):I期试验

Safety and early organ preservation outcomes after dose escalation with MR-guided radiotherapy for rectal cancer (preRADAR): A phase I trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-05-25

preRADAR是一项I期剂量递增试验,评估中危直肠癌患者接受短程放疗(SCRT;5×5 Gy)后采用MR引导放疗(MRgRT)进行GTV加量的最大耐受剂量。剂量水平2(SCRT+4×5 Gy加量)为在DLT停止边界内完成的最高剂量水平,26周器官保留率为56%(5/9)。

要点

  • SCRT后MRgRT加量至4×5 Gy在预设DLT边界内安全可行。
  • 所有适应性加量分次均达到PTV V95%>90%的可行性标准。
  • 剂量水平2的26周器官保留率为56%(5/9)。

核心结论

  • 基于MRgRT的SCRT后剂量递增在中危直肠癌中安全可行,最高评估剂量水平(SCRT后4×5 Gy GTV加量)在预设DLT边界内被认为安全,值得进一步评估。

研究设计与样本

  • I期剂量递增试验(preRADAR),采用6+3设计,纳入T3c-d(MRF-)N0M0或T1-3(MRF-)N1M0的中危直肠癌患者,在1.5 Tesla MR-linac上接受SCRT(5×5 Gy)后根据剂量水平进行2-4次每日5 Gy的GTV加量。

主要发现

  • 所有分次均按计划完成,所有适应性加量分次均达到预设可行性标准(PTV V95%>90%)。
  • 未发生急性DLT;观察到3例围手术期DLT,包括2例需再次手术的吻合口漏。
  • 未确定MTD;剂量水平2(SCRT+4×5 Gy加量)为在DLT停止边界内完成的最高剂量水平,26周器官保留率为56%(5/9)。

关键数值与推荐

  • 可行性标准:加量PTV V95%>90%。
  • DLT在预设时间窗和停止边界内评估。
  • 剂量水平2的26周器官保留率为56%(5/9)。

临床怎么用

  • 中危直肠癌患者可考虑SCRT后MRgRT加量至4×5 Gy,但需在临床试验框架内进一步评估。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Organ preservation is a desirable goal for patients with rectal cancer. Magnetic resonance-guided radiotherapy (MRgRT) enables precise dose delivery and online adaptation. This phase I study (preRADAR) evaluated maximum tolerated dose (MTD) of short course radiotherapy (SCRT; 5x5 Gy) with a subsequent boost using MRgRT in intermediate-risk rectal cancer. MATERIALS AND METHODS: the trial had a 6 + 3 dose-escalation design. Patients staged T3c-d(MRF-)N0M0 or T1-3(MRF-)N1M0 were treated on a 1.5 Tesla MR-linac with short-course radiotherapy (SCRT; 5 × 5 Gy) followed by 2-4 daily 5 Gy GTV boosts according to the dose level. Safety was assessed by incidence of acute and perioperative dose-limiting toxicities (DLTs) within prespecified time windows and stopping boundaries. Secondary endpoints included technical feasibility (boost PTV V95% > 90%) and organ preservation at six months. RESULTS: Out of 31 patients screened, sixteen were treated across three dose levels. All fractions were delivered as planned and all adaptive boost fractions achieved the predefined feasibility criterion (PTV V95% >90%). No acute DLTs occurred. Three perioperative DLTs were observed, including two anastomotic leaks requiring reoperation. The MTD was not identified; dose level 2 (SCRT + 4 × 5 Gy boosts) was the highest dose level completed within the DLT stopping boundaries, achieving a 26-week organ preservation rate of 56% (5/9). CONCLUSION: MRgRT-based enables dose escalation following SCRT in intermediate-risk rectal cancer. The highest evaluated dose level, 4 × 5 Gy GTV boosts after SCRT, was considered safe within the predefined DLT boundaries and feasible for further evaluation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Eijkelenkamp H, Verweij ME, Grimbergen G, et al. Safety and early organ preservation outcomes after dose escalation with MR-guided radiotherapy for rectal cancer (preRADAR): A phase I trial. Clin Transl Radiat Oncol. 2026. PMID: 42290893. doi:10.1016/j.ctro.2026.101191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。